Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion.
Chemotherapy induced peripheral neurotoxicity
cancer survivorship
exercise
neurotoxicity
outcome measures
peripheral neuropathy
rehabilitation
treatment
Journal
Expert review of neurotherapeutics
ISSN: 1744-8360
Titre abrégé: Expert Rev Neurother
Pays: England
ID NLM: 101129944
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
pubmed:
14
12
2021
medline:
5
4
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
Chemotherapy-induced peripheral neurotoxicity (CIPN) remains a significant toxicity in cancer survivors without preventative strategies or rehabilitation. Exercise and physical activity-based interventions have demonstrated promise in reducing existing CIPN symptoms and potentially preventing toxicity, however there is a significant gap in evidence due to the lack of quality clinical trials and appropriate outcome measures. We systematically reviewed outcome measures in CIPN exercise and physical rehabilitation studies with expert panel consensus via the Peripheral Nerve Society Toxic Neuropathy Consortium to provide recommendations for future trials. Across 26 studies, 75 outcome measures were identified and grouped into 16 domains within three core areas - measures of manifestations of CIPN (e.g. symptoms/signs), measures of the impact of CIPN and other outcome measures. This article provides a conceptual framework for CIPN outcome measures and highlights the need for definition of a core outcome measures set. The authors provide recommendations for CIPN exercise and physical rehabilitation trial design and outcome measure selection. The development of a core outcome measure set will be critical in the search for neuroprotective and treatment approaches to support cancer survivors and to address the gap in the identification of effective rehabilitation and treatment options for CIPN.
Identifiants
pubmed: 34894974
doi: 10.1080/14737175.2022.2018300
pmc: PMC8963967
mid: NIHMS1766901
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Systematic Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
65-76Subventions
Organisme : NCI NIH HHS
ID : K07 CA221931
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA256154
Pays : United States
Références
Ther Adv Med Oncol. 2017 May;9(5):369-382
pubmed: 28529552
CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37
pubmed: 24590861
J Peripher Nerv Syst. 2014 Jun;19(2):127-35
pubmed: 24814100
J Peripher Nerv Syst. 2007 Sep;12(3):210-5
pubmed: 17868248
J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1361-1369
pubmed: 31256000
Ann Oncol. 2020 Oct;31(10):1306-1319
pubmed: 32739407
Clin Breast Cancer. 2019 Dec;19(6):411-422
pubmed: 31601479
Am J Phys Med Rehabil. 2020 Apr;99(4):291-299
pubmed: 31592877
Support Care Cancer. 2019 Jun;27(6):2159-2169
pubmed: 30288602
J Cancer Surviv. 2021 Mar 12;:
pubmed: 33710510
Neurology. 2018 Aug 28;91(9):403-413
pubmed: 30054438
J Peripher Nerv Syst. 2019 Sep;24(3):242-246
pubmed: 31222873
Chest. 2020 Mar;157(3):603-611
pubmed: 31689414
Qual Life Res. 2021 Jan;30(1):21-40
pubmed: 32926299
Ann Oncol. 2014 Feb;25(2):493-9
pubmed: 24478323
Int J Rehabil Res. 2016 Dec;39(4):368-371
pubmed: 27749517
J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S4-S5
pubmed: 31647150
Gait Posture. 2017 Oct;58:325-332
pubmed: 28865394
J Rheumatol. 2019 Aug;46(8):1021-1027
pubmed: 30770515
BMC Cancer. 2019 May 2;19(1):414
pubmed: 31046719
Ann Neurol. 2017 Jun;81(6):772-781
pubmed: 28486769
Br J Cancer. 2021 Sep;125(7):955-965
pubmed: 34226683
Neurorehabil Neural Repair. 2020 Mar;34(3):235-246
pubmed: 31976819
Gerontology. 2016;62(5):553-63
pubmed: 26678611
Cancer Nurs. 2020 Jul/Aug;43(4):269-280
pubmed: 30888982
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Cancer Res Clin Oncol. 2018 Sep;144(9):1785-1792
pubmed: 29943097
Support Care Cancer. 2018 Apr;26(4):1019-1028
pubmed: 29243164
Support Care Cancer. 2018 Sep;26(9):3143-3151
pubmed: 29594485
J Altern Complement Med. 2020 Jun;26(6):449-455
pubmed: 32167801
J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):392-8
pubmed: 23813745
Support Care Cancer. 2021 Jun;29(6):2993-3008
pubmed: 33030598
Asian Pac J Cancer Prev. 2021 Mar 01;22(3):705-709
pubmed: 33773532
Support Care Cancer. 2020 Apr;28(4):1991-1995
pubmed: 31378844
Exp Hematol Oncol. 2017 Feb 7;6:5
pubmed: 28194306
J Peripher Nerv Syst. 2011 Sep;16(3):228-36
pubmed: 22003937
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419850627
pubmed: 31131640
Support Care Cancer. 2019 Oct;27(10):3849-3857
pubmed: 30756229
Support Care Cancer. 2019 Jul;27(7):2471-2478
pubmed: 30382392
J Clin Oncol. 2020 Oct 1;38(28):3325-3348
pubmed: 32663120
J Natl Cancer Inst. 2019 Jun 1;111(6):531-537
pubmed: 30715378
Cancer Nurs. 2020 May/Jun;43(3):E172-E185
pubmed: 32187026
Ann Oncol. 2014 Jan;25(1):257-64
pubmed: 24256846
Support Care Cancer. 2014 Jan;22(1):95-101
pubmed: 23995813
JNCI Cancer Spectr. 2020 Jun 04;4(6):pkaa048
pubmed: 33225208
J Frailty Aging. 2021;10(2):141-149
pubmed: 33575703
Support Care Cancer. 2018 Feb;26(2):615-624
pubmed: 28963591
Aging Clin Exp Res. 2018 Jan;30(1):1-16
pubmed: 28374345
J Pain. 2020 Jan - Feb;21(1-2):44-58
pubmed: 31325646
Eur J Oncol Nurs. 2020 Dec;49:101834
pubmed: 33120223
Asia Pac J Oncol Nurs. 2021 Mar 26;8(3):255-266
pubmed: 33850959